Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Vietnam Investment Review on MSN2d
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular CarcinomaLion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...
China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...
CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
You will be redirected to our submission process. Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal malignancies. BTC stands ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback